{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T19:08:34Z","timestamp":1781550514964,"version":"3.54.5"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Acquired hemophilia A (AHA) is a rare but potentially life-threatening autoimmune bleeding disorder and immune-related adverse event (irAE) associated with immune checkpoint inhibitors (ICI). This study discusses 3 new cases of ICI-induced AHA from Belgium and the SERIO-Side Effect Registry Immuno-Oncology (www.serio-registry.org), placing them in the context of existing literature.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>One case was encountered at a tertiary care center in Belgium. SERIO was queried and yielded another 2 cases. A comprehensive literature review using PubMed identified 8 additional cases.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 11 patients were analyzed, with a median age of 68\u2009years (range: 56-71), 10 were male. Most (9\/11) were treated with anti-PD-1 monotherapy. In 5 cases, toxicity appeared before the fourth cycle. Immunosuppressive therapy successfully achieved complete resolution of AHA in 9 of 11 patients. For the first time, one patient was successfully treated with emicizumab, a monoclonal bispecific antibody, which bridges activated factor IX and factor X.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Clinicians should be vigilant about ICI-induced AHA as a potentially severe irAE. Prolonged aPTT requires thorough evaluation. Upon AHA confirmation, eradication of anti-FVIII antibodies with corticosteroids, rituximab, or other immunosuppressant should be attempted. Emicizumab offers advantages over traditional replacement therapy, including ease of use and a potential reduction in immunosuppressive drug requirements\u2014an important consideration in ICI-treated patients. Further research is needed to fully understand the pathophysiology and optimize treatment strategy for AHA.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf260","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T17:47:43Z","timestamp":1755625663000},"source":"Crossref","is-referenced-by-count":2,"title":["Acquired hemophilia due to immune checkpoint inhibitors: a case series introducing emicizumab treatment"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9955-5433","authenticated-orcid":false,"given":"Louis","family":"Wolff","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Institut Jules Bordet, H\u00f4pital Universitaire de Bruxelles (H.U.B.), Universit\u00e9 Libre de Bruxelles (ULB) , Brussels 1070,","place":["Belgium"]},{"name":"Belgian Multidisciplinary Immunotoxicity Board (BITOX)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Ertl","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, LMU University Hospital, LMU Munich , Munich 80336,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5718-3643","authenticated-orcid":false,"given":"Lucie","family":"Heinzerling","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, LMU University Hospital, LMU Munich , Munich 80336,","place":["Germany"]},{"name":"Department of Dermatology, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg (FAU), Universit\u00e4tsklinikum Erlangen , Erlangen 91054,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6598-9161","authenticated-orcid":false,"given":"Sandrine","family":"Aspeslagh","sequence":"additional","affiliation":[{"name":"Belgian Multidisciplinary Immunotoxicity Board (BITOX)"},{"name":"Department of Medical Oncology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel) , Brussels 1090,","place":["Belgium"]},{"name":"Department of Internal Medicine, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel) , Brussels 1090,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3054-7969","authenticated-orcid":false,"given":"Marthe","family":"Verhaert","sequence":"additional","affiliation":[{"name":"Belgian Multidisciplinary Immunotoxicity Board (BITOX)"},{"name":"Department of Medical Oncology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel) , Brussels 1090,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Lattenist","sequence":"additional","affiliation":[{"name":"Department of Hematology, P\u00f4le Hospitalier Jolimont, R\u00e9seau HELORA , Haine Saint-Paul 7100,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Confente","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, P\u00f4le Hospitalier Jolimont, R\u00e9seau HELORA , Haine Saint\u2011Paul 7100,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Lambert","sequence":"additional","affiliation":[{"name":"Unit\u00e9 d\u2018h\u00e9mostase-thrombose, Service d\u2018h\u00e9matologie, Cliniques universitaires Saint-Luc, UCLouvain , Brussel 1200,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Ilzkovitz","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Institut Jules Bordet, H\u00f4pital Universitaire de Bruxelles (H.U.B.), Universit\u00e9 Libre de Bruxelles (ULB) , Brussels 1070,","place":["Belgium"]},{"name":"Belgian Multidisciplinary Immunotoxicity Board (BITOX)"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,19]]},"reference":[{"key":"2025100119312567200_oyaf260-B1","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.3389\/fimmu.2020.01354","article-title":"Diagnosis and management of hematological adverse events induced by immune checkpoint inhibitors: a systematic review","volume":"11","author":"Omar","year":"2020","journal-title":"Front Immunol"},{"key":"2025100119312567200_oyaf260-B2","doi-asserted-by":"publisher","first-page":"113505","DOI":"10.1016\/j.ejca.2023.113505","article-title":"The side effect registry immuno-oncology (SERIO) - a tool for systematic analysis of immunotherapy-\u00adinduced side effects","volume":"199","author":"Ertl","year":"2024","journal-title":"Eur J Cancer"},{"key":"2025100119312567200_oyaf260-B3","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.jtha.2022.10.004","article-title":"A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A","volume":"21","author":"Shima","year":"2023","journal-title":"J Thromb Haemost"},{"key":"2025100119312567200_oyaf260-B4","doi-asserted-by":"publisher","first-page":"e913","DOI":"10.1016\/S2352-3026(23)00280-6","article-title":"Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 study","volume":"10","author":"Tiede","year":"2023","journal-title":"Lancet Haematol"},{"key":"2025100119312567200_oyaf260-B5","doi-asserted-by":"publisher","first-page":"10760296241298661","DOI":"10.1177\/10760296241298661","article-title":"Outcomes of emicizumab in acquired hemophilia patients: a systematic review","volume":"30","author":"Ikbel","year":"2024","journal-title":"Clin Appl Thromb Hemost"},{"key":"2025100119312567200_oyaf260-B6","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1056\/NEJMc111092322047582","article-title":"Hemophilia a induced by ipilimumab","volume":"365","author":"Delyon","year":"2011","journal-title":"N Engl J Med"},{"key":"2025100119312567200_oyaf260-B7","doi-asserted-by":"publisher","first-page":"e560","DOI":"10.1016\/j.cllc.2019.06.022","article-title":"Acquired hemophilia a after nivolumab therapy in a patient with metastatic squamous cell carcinoma of the lung successfully managed with rituximab","volume":"20","author":"Gokozan","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"2025100119312567200_oyaf260-B8","doi-asserted-by":"publisher","first-page":"e239","DOI":"10.1016\/j.jtho.2018.06.024","article-title":"Nivolumab-induced hemophilia a presenting as gastric ulcer bleeding in a patient with NSCLC","volume":"13","author":"Kato","year":"2018","journal-title":"J Thorac Oncol"},{"key":"2025100119312567200_oyaf260-B9","doi-asserted-by":"publisher","first-page":"100409","DOI":"10.1016\/j.jtocrr.2022.100409","article-title":"Acquired hemophilia a secondary to an immune checkpoint inhibitor: a case report","volume":"3","author":"Fletcher","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"2025100119312567200_oyaf260-B10","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.3390\/diagnostics12102559","article-title":"A diagnostic of acquired hemophilia following PD1\/PDL1 inhibitors in advanced melanoma: the experience of two patients and a literature review","volume":"12","author":"Gidaro","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"2025100119312567200_oyaf260-B11","doi-asserted-by":"publisher","first-page":"S524","DOI":"10.1016\/S2152-2650(23)01504-5","article-title":"CT-277 acquired hemophilia A: an unusual complication of immune checkpoint inhibitors","volume":"23","author":"Gandour","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"2025100119312567200_oyaf260-B12","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1097\/MBC.0000000000001244","article-title":"Acquired bleeding disorders secondary to immune checkpoint inhibitors: a case report and systematic literature review","volume":"34","author":"Archibald","year":"2023","journal-title":"Blood Coagul Fibrinolysis Int J Haemost Thromb"},{"key":"2025100119312567200_oyaf260-B13","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.3324\/haematol.2019.230771","article-title":"International recommendations on the diagnosis and treatment of acquired hemophilia A","volume":"105","author":"Tiede","year":"2020","journal-title":"Haematologica"},{"key":"2025100119312567200_oyaf260-B14","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.thromres.2024.03.012","article-title":"Cyclophosphamide vs rituximab for eradicating inhibitors in acquired hemophilia A: a randomized trial in 108 patients","volume":"237","author":"L\u00e9vesque","year":"2024","journal-title":"Thromb Res"},{"key":"2025100119312567200_oyaf260-B15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.clicom.2024.04.001","article-title":"First reported use of immune checkpoint inhibitor for treatment of cancer in a patient with acquired hemophilia A","volume":"5","author":"Mostafa","year":"2024","journal-title":"Clin Immunol Commun"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf260\/64084966\/oyaf260.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/10\/oyaf260\/64084966\/oyaf260.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/10\/oyaf260\/64084966\/oyaf260.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T23:31:36Z","timestamp":1759361496000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf260\/8238170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,19]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf260","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,8,19]]},"article-number":"oyaf260"}}